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Abstract
Prohibition of illegal drugs is a failed social policy and new models of regulation of these substances
are needed. This paper explores a proposal for a post-prohibition, public health based model for
the regulation of the most problematic drugs, the smokable and injectable stimulants. The literature
on stimulant maintenance is explored. Seven foundational principles are suggested that could
support this regulatory model of drug control that would reduce both health and social problems
related to illegal stimulants. Some details of this model are examined and the paper concludes that
drug policies need to be subject to research and based on evidence.
Commentary
The global movement toward recognizing the failure of
drug prohibition is growing. This is partly due to the
emergent understanding that drug prohibition is the
dominant driver behind the creation of a illegal market
that spawns significant health and social pathologies,
harmfully engages our youth, and makes impure illegal
drugs widely available. In Canada the concept of a regu-
lated market has been proposed as an alternative to drug
prohibition [1-3] and this reflects the growing interna-
tional movement [4-6]. One of the next steps toward evi-
dence-based drug policies is to develop specific models of
drug control for each of the different classifications of
drugs. These models should be able to demonstrate that
their implementation would produce less harm than the
current prohibitionist model. Different types of drugs will
need different models of control due to their widely differ-
ing pharmacological attributes. The smokeable and inject-
able stimulants have a wide range of potential harms and
therefore pose a considerable challenge to those propos-
ing new, public health based models of drug control. The
goal of this paper is to address this challenge and explore
a specific model that could be used in a post-prohibition
paradigm to reduce the harms caused by these specific
substances. This paper will explore some of what is known
about the patterns of stimulant drug use and recommend
a more optimal policy direction than the current prohibi-
tionist model.
The mass media in Canada describe the use of crystal
methamphetamine as a plague [7] or epidemic [8] and
warns of marijuana laced with crystal methamphetamine
even when no contaminated marijuana is seized by the
police [9]. Poll reports indicate that the media exaggerate
the prevalence of use. In schools, use of crystal metham-
phetamine is likely very limited, as only 4–5% of students
report having ever used this drug [10]. This use was prob-
ably not by injection, as reports show that only between
0–1% of students have ever injected drugs [10,11]. Use of
cocaine by students is also low, at about 5% [11]. These
usage rates are in sharp contrast to marijuana use rates, as
over half of British Columbia's 17 year olds report having
used this drug [11]. The use patterns of injectable or
smokable stimulants are limited to the most marginalized
populations, such as street youth, where frequency of use
is significant and may be increasing. In the street youth
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population, 67–71% have used amphetamines and 57%
have used them more than 10 times [12]. In Canada use
of crack cocaine follows a similar pattern where the use is
restricted to marginalized populations [13] and this same
pattern is seen in the United States as well [14].
If an intervention is to be successful at reducing the health
and social problems associated with stimulant drugs, it
must at a minimum, be able to alter the behaviour of indi-
viduals who inject and smoke these drugs. Drug law
enforcement is currently the predominant response to the
problems created by illegal drugs use, with Canadians
spending approximately CA$2.3 billion on direct law
enforcement costs and CA$1.1 billion on health costs
[15]. Because our society continues to approach drug use
as primarily a criminal problem rather than a health prob-
lem we suffer from the ineffectiveness of this approach
[16-20]. We are also burdened by health and social prob-
lems which are the unanticipated outcomes of prohibi-
tion [1,21].
These increased health and social problems created by
drug prohibition can be attributed to three likely causes.
The first is that enforcement interventions themselves are
directly responsible for the creation of harmful health and
social impacts. This is due to the fact that enforcement
activities create a disruption of health service provision to
drug users and as a result there is increased risk-taking
behaviours associated with infectious disease transmis-
sion and overdose [22]. Fast, surreptitious, back-alley
injections are rarely safe and hygienic.
Secondly, drug prohibition prevents the exploration of
the potential benefits of currently illegal drugs, which
could be used in the treatment of drug users. For example
initial research has suggested that cannabis can be useful
in hepatitis C treatment as it improves patient retention
and outcomes in programs designed to treat this disease
[23,24].
The third and most important reason is that the enforce-
ment paradigm prevents the establishment of a regulated
system of drug control that could more effectively miti-
gate the harms associated with illegal drug use. The discus-
sion of a regulated market for all currently illegal drugs
has recently been legitimised in Canada with the release of
the three reports, one federal [3] one provincial [25] and
one from the City of Vancouver [2]. All of these reports are
significant as they move beyond criticisms of drug prohi-
bition and recommend the creation of a regulated market
for currently illegal drugs. It is therefore timely to consider
how a public health model of drug control could reduce
many of the health and social problems associated with
these substances. A regulated market system could control
who could access drugs, the training that users receive,
and the context in which these substances are consumed.
These controls can be predicted to reduce many health
and social pathologies that are currently associated with
the use of illegal stimulants.
Heroin maintenance, as a treatment regimen for opioid
dependence, has existed in some countries for many years
[26,27] and while there are important lessons that have
been learned from this experience [28], there are unique
features to establishing a stimulant maintenance pro-
gram. As a result, effective control of stimulants needs to
be considered as a separate and distinct challenge. Formu-
lating an effective model for stimulant control is impor-
tant in the discussion of the prevention of diseases like
HIV/AIDS and hepatitis C, as this class of drugs poses a
significant challenge to public health officials due to the
frequent injection of these drugs [29] and the sometimes
erratic behaviour of those engaging in this high-risk
behaviour. The challenge of creating a rational public
health response that is both compassionate and effectively
controls stimulant use is perhaps one of the more difficult
tasks faced by advocates of drug policy reform. In order to
do this, it is appropriate to examine the existing work that
has been done on stimulant maintenance.
Dexamphetamine was prescribed to 63 intravenous
amphetamine users by McBride and colleagues who
observed significant improvements in both health and
social functioning of these individuals [30]. A low dosage
oral amphetamine project was conducted over three years
by Fleming and Roberts, who reported that this program
helped patients to cease or reduce injecting and other risk
behaviours, and the authors also noted an increase in
users presenting for treatment [31]. In a pilot randomized
double blind controlled study, Shearer found that those
who were given dexamphetamine reported a reduction in
cocaine use, criminal behaviour, and cravings for cocaine
[32]. Sustained-release d-amphetamine was used by
Grabowski in his treatment of cocaine dependence for cli-
ents on methadone [33]. When amphetamine was pre-
scribed to patients with schizophrenia and amphetamine
dependence, Carnwath and colleagues observed a benefit
[34]. A brief positive report is offered by Sherman who
treated 13 patients for methamphetamine addiction by
giving them stable dosages of dexamphetamine [35]. Pre-
scribing amphetamines is not uncommon in the UK as
Strang estimated there were 900–1000 patients receiving
amphetamines for the treatment of addiction in England
and Wales [36]. Bruce observes that the Department of
Health Guidelines in London indicate that the prescrip-
tion of dexamphetamine is at times, appropriate. He
examines a variety of treatment approaches for ampheta-
mine dependence and concludes that under some circum-
stances, prescription of amphetamines is an option that
should be explored [37]. A review article by Mattick andHarm Reduction Journal 2008, 5:1 http://www.harmreductionjournal.com/content/5/1/1
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Darke explored concerns and offered tentative optimism
about stimulant maintenance [38]. The literature on stim-
ulant maintenance is also reviewed by Fleming, who con-
cluded that this is a valid and useful treatment process
[39]. This was echoed by Alexander who also did a litera-
ture review and concluded that stimulant maintenance
could be a successful, pragmatic innovation [40].
An examination of the literature above leads to the con-
clusion that giving dependent users controlled access to
stimulants has the potential to reduce risky and illegal
behaviours and therefore improve health and social func-
tioning. These papers start to challenge the basic assump-
tions of drug prohibition, but they do so only by
implication. They do not go far enough and deal directly
with the actual problem of prohibition itself, which is the
paradigm that is responsible for such high infection rates
and has spawned so many other health and social pathol-
ogies [1,21]. The goal of this paper is to move forward by
thinking out of the "prohibition box" and suggesting a
specific public health model of stimulant control that
would significantly reduce or eliminate the illegal market,
and therefore considerably reduce both the health and
social problems associated with these compounds. In
order to do this, seven foundational principles need to be
explored:
Principle 1: The goal is to reduce harm
While the goal of reducing harm may sound self-evident,
it has not always been clear that this is the primary policy
objective. The 1998 United Nations General Assembly
Special Session on Drugs urged member states to work
towards the goal of "a drug-free world by 2008" [41]. This
goal entrenches the enforcement approach, and has para-
doxically increased both health and social harms and pro-
duced a illegal market that makes drugs widely available.
What is needed is a public health model of drug control
that is driven by evidence and clearly establishes prag-
matic, realistic, achievable targets for the reduction of
harms to individuals, families and all of society.
Principle 2: Social Capital needs to be increased
The concept of social capital [42-44] should be founda-
tional in the post prohibition paradigm. This concept cor-
relates strong, healthy, supportive and multigenerational
bonds between individuals in families, schools, and com-
munities with many health, social and economic benefits
[45,46]. To put this concept simply: relationships have
value. Those who have abundant social networks and the
reciprocities which flow from them are happier, healthier
and wealthier. The opposite is also true as marginalized,
alienated individuals who are disconnected from a variety
of supports suffer significant harms that result in many
health, social and economic impacts [47]. The lens of
social capital elucidates how social networks impact drug
use [48] and is especially useful in understanding youth
drug use [49]. Students with strong connections to family,
school and community are healthier and were less likely
to smoke cigarettes and marijuana or drink alcohol [11].
It was observed that resilience could be improved in vul-
nerable youth by improving school and family connec-
tions [50]. Social capital is also a concept vital to the
understanding of disease risk factors and infection control
[51]. Increase in social capital is also important for those
who are recovering from substance abuse [52-54]. This
concept is also significant from a community perspective.
Mheen observed the role of social capital in keeping drug
dealers from infiltrating into neighbourhoods, as illegal
markets tend to flourish in areas where poor social cohe-
sion results in difficulty regulating nuisance and problem-
atic behaviours [55]. Ford explored how a drug market
becomes established due to poor social capital and sug-
gested that a regulated drug trade would support the well
being of drug users and minimize nuisance factors [56].
The issue of social capital is also observed in research that
explores aboriginal ayahuasca and peyote rituals that pro-
mote social cohesion and have demonstrated individual
and community benefit [57-59]. This exploration suggests
that marginalized drug users, who are most at risk for the
transmission of diseases, can be greatly benefited by the
increase of social capital in their lives. If the goal is to
reduce or eliminate risky behaviours, increasing their
strong and supportive bonds will be crucial to this proc-
ess.
Principle 3: The culture of drug use needs to be understood 
and influenced
Effective control of infectious diseases and social prob-
lems associated with illegal drugs will only be realized
when the culture of drug use is understood and influ-
enced. Drug use patterns within communities need to be
understood as cultural patterns in that they are governed
by a wide variety of social normative behaviours and ritu-
als. This perspective is helpful in rethinking risk and risk
management [60,61]. The complex and richly rewarding
study of cross-cultural drug use [62-64] is very helpful in
the development of an effective post prohibition model of
drug control. For a model to be effective in the control of
stimulant use, it would have to engage the drug using
community in developing a new drug using culture that
works actively to reduce harms. This culture could posi-
tively influence how, where and when drugs are used, and
specify acceptable behaviours for those who are using
these substances. The effect of a positive change in the
drug using culture was observed in Switzerland where the
incidence of heroin use dropped as the use of heroin was
reframed as a behaviour that required medical attention.
The Swiss successfully shifted the image of heroin use and
made it unattractive for young people [65] and it is nota-
ble that this drop in use occurred in spite of fact that theHarm Reduction Journal 2008, 5:1 http://www.harmreductionjournal.com/content/5/1/1
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Swiss are criticized for their pragmatic drug policies. The
confines of the prohibitionist framework discourage the
implementation of interventions that would support the
positive evolution of the drug culture. This is because
interventions that could create positive new behaviour
patterns and protective social norms are extremely diffi-
cult to implement within the prohibitionist model.
Principle 4: The goal is to use the "least restrictive" 
intervention
The principle of "least restrictiveness" states that each drug
should be controlled using methods that are as minimally
restrictive as is possible given that the goal is to achieve
specific health and social outcomes. There are both
human rights and economic justifications for this princi-
ple as both respect for individual autonomy and cost sav-
ings are important. Adopting this principle requires
achieving a balance between the potential harmfulness of
a drug with the appropriate level of control. There is a sig-
nificant range of preparations of stimulant drugs available
that have different potentials for harm. On one end of this
continuum is a weak oral solution (chewing coca leaves,
and drinking coca leaf tea). In the middle is "snorting" of
a more concentrated powder, and at the riskiest end is the
smoking and injecting of more highly concentrated prod-
ucts. South American indigenous peoples have drunk coca
tea and chewed the leaves for over 3000 years [66], often
on a daily basis with no harms to the individuals, families
or communities [67,68]. On the other end of the spec-
trum are the significant problems that marginalized indi-
viduals experience when these drugs are injected or
smoked in chaotic use patterns. Across the whole spec-
trum, it can be observed that the concentration of the
product and the method of taking the drug and the con-
text combine to produce a wide range of possible harms.
The "least restrictiveness principle" requires that sub-
stances with greater potential for harm, like injectable or
smokable preparations of cocaine, be controlled with
more restrictive mechanisms. Less harmful preparations
such as coca tea, can be appropriately controlled with
social norms and rituals and therefore need fewer and less
restrictive administrative interventions.
Principle 5: Prevention and treatment are vital
A vital aspect of a post prohibition model is the need for
effective treatment and prevention programs. Only after
prohibition ends can these programs flourish, as the
effects of prohibition are in direct opposition to the goals
of effective treatment and prevention. There are (at least)
two reasons why this is true. Prohibition impairs the
development of honest, factual prevention programs [69-
72] and prohibition marginalizes, and alienates drug
users and this produces many health and social conse-
quences. This fact has been explored in many significant
Canadian reports [2,73-76]. The City of Vancouver report;
Preventing Harm From Psychoactive Substance Use [77],
explored in detail how a regulated market for currently
illegal drugs is a basic requirement if the city is going to
significantly impact the drug problems its citizens so often
experience. Looking at prevention and treatment pro-
grams through a post prohibition lens allows these con-
cepts to be expanded to embrace the social determinants
of health (e.g. housing, poverty, empowerment, commu-
nity cohesiveness) that are foundational to a public health
understanding of addiction. There is a connection
between the prevention and treatment literature and the
social capital research. Effective prevention and treatment
programs could have as a goal to increase the social capital
in the lives of the participants or community residents.
Another reason why prohibition is detrimental to the pro-
vision of treatment and prevention programs is that pro-
hibition of drugs is a very expensive process. When
examined through the lens of the Federal Drug Strategy it
is observed that enforcement costs absorb 73% of the
budget, treatment receives 14% and prevention receives
3% [78]. In order to provide effective and responsive treat-
ment and prevention programs they would have to receive
adequate funding and as tax dollars are always scarce, this
dramatic imbalance would need to be rectified.
Principle 6: Learn the lessons from alcohol and tobacco
We need to reflect on the lessons learned from the regula-
tion of alcohol and tobacco as we develop a post prohibi-
tion model of stimulant control. These products have
historically been under-regulated [25,79] and it is impor-
tant to not repeat these errors. When a product is allowed
to be branded, the battle to control the advertising of it is
relentless [80]. Only in a tightly controlled government
regulated system could the presentation of a product be
consistently uniform and deliberately unattractive [81].
Principle 7: Changes need to occur incrementally
Drug policy needs to change incrementally as policy mak-
ers need time to gather evidence and change direction
based on collected data. The public also needs time in
order to be reassured that the change is beneficial and that
we are moving toward the goals of reducing the health
and social problems associated with illegal drugs. Health
harms are related to the spread of disease and premature
death. Social harms are mostly related to the functioning
of the illegal market, which is responsible for the violence,
crime, corruption, uncontrolled availability of drugs, and
the engagement of youth into the drug scene. Data collec-
tion on all of these issues at each incremental step will be
important for policy makers and the public. Response to
this data is vital as policy can be stabilized when the illegal
market is significantly decreased or eliminated and drug
users are in safe environments.Harm Reduction Journal 2008, 5:1 http://www.harmreductionjournal.com/content/5/1/1
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There are a variety of increments that can be used. Ini-
tially, policies might allow only drug-dependent adults to
legally access substances. Then, as health and social
improvements are demonstrated in this population,
adults who use drugs problematically could be included.
If positive data continues to emerge and the illegal market
is still functional, the next step would be to include drug
using adults who have been trained in ways of reducing
potential harms. Increments can also be based on drug
price. Substances can initially be priced at 80% of the ille-
gal market price, and if the illegal drugs are still widely
available, the price can slowly be reduced until the illegal
market either ceases to function or is substantially
reduced to the point where it produces minimal harms.
Increments could also be based on "order-delivery delay
time". Initially there could be a delay of 48 hours between
customer order and delivery of the product. This would
reduce the chance of uncontrolled sequential use. This
delay time could be reduced as the size of the illegal mar-
ket was monitored. Delay time could be stabilized at the
point at which the illegal market is reduced to a size where
it inflicts minimal health and social damage. Another
incremental change could be based on geography, as one
neighbourhood could be selected for a pilot study and as
benefit is proven the area could then be expanded. Type of
drug preparation that is available, could also be incremen-
tally changed. Initially only weak oral solutions could be
purchased, and in response to the evidence, stronger prep-
arations could be made available. There can also be a slow
incremental transition from administrative to social con-
trols as our society becomes more sophisticated at influ-
encing the social norms that control drug use patterns and
drug user groups mature and evolve to take more respon-
sibility for the behaviour of their members.
When the above seven principles are combined in a public
health model, we can make specific drug control policy
recommendations, and we can replace the prohibition of
stimulants with a more rational policy that would signifi-
cantly reduce the health and social problems associated
with stimulant drugs.
While there are many types of controls that could be used
[4,5,82] this paper will explore only a few of these that
show promise for specifically reducing the health and
social problems associated with injectable and smokeable
stimulants. The following controls are based on the above
principles:
Age
These substances should not be sold to youth under the
age of 19, as we have learned from our experience with
alcohol and tobacco that we can reduce access in the
youth population with age controls [83].
Required training prior to purchase
Consumers of more concentrated products need to be
enrolled in a training program that provides them with
information about how to reduce or avoid harm. This
training would have a prevention and treatment focus,
and would cover both prevention of harms and access to
services, for those who need treatment for substance
dependence.
Required consumption of drugs at a safe, health promoting facility
As concentrated injectable and smokeable stimulants
need to be removed from the illegal market, take out dos-
ages should not be available. These substances will need
to be consumed at a supervised consumption site where
they are dispensed. The behaviour of individuals using
smokeable and injectable stimulants can become erratic,
therefore consumers need to be observed to provide
assistance or intervention. These health facilities need to
be clean and engaging. Health care workers and peers
could monitor consumers and, if indicated, provide assist-
ance and referrals to other components of the addiction
treatment system. InSite, Vancouver's supervised injection
facility provides assistance and referrals to other treatment
services [84] and this is consistent with the experience in
other countries. For example the Swiss heroin prescription
trial was successful in engagement of drug users as 22% of
the clients went on to become involved in abstinence
based services [85].
Voluntary and involuntary "cut-offs" should be available
As problematic binge use of stimulant drugs is observed in
some individuals, "cut-offs" need to be established. The
"least restrictive" principle dictates that initially "cut offs"
should be voluntary where the consumption room staff
negotiate in advance with the customer and plan for con-
sumption levels. If this is not an adequate intervention
and problematic behaviours are observed, then involun-
tary "cut-offs" would be needed to assist those who are
experiencing harm from these substances.
Membership in a drug users group would be required
One of the goals of an effective drug policy will be to both
increase social capital and directly influence the culture of
the drug using community. This can be achieved through
sharing of responsibility where drug user groups would be
established and then held partially responsible for the
behaviour of their members. These drug user groups will
need to be legitimate, secure and adequately funded. They
would function as licensed bodies, and would be required
to provide peer training. Group members would assist in
running consumption facilities and work with peer pres-
sure to reduce harmful behaviours. These groups would
ideally be comprised of individuals from many sectors of
society and would be able to provide public education
with the goal of changing the social norms that influenceHarm Reduction Journal 2008, 5:1 http://www.harmreductionjournal.com/content/5/1/1
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all drug users. As the intention is to increase social capital
within this community, users will need to participate in a
legitimate and meaningful way [86]. In return for this
legitimacy, accountability for specific outcomes (e.g. no
criminality for members) would be required.
The above model is designed to be applied to smokable or
injectable stimulants, which have significant potential for
harms [87]. Controls for a weak oral solution of cocaine
and amphetamines should, as per the "least restrictive-
ness" principle, be significantly less than for the concen-
trated product as the potential for harm is much lower.
Controls similar to those that exist in Canada for tobacco
and alcohol would be sufficient for these products, with
the significant exception of product branding and market-
ing, which would contribute to the increased consump-
tion of these drugs. Therefore items like coca tea would be
available to any adult, in plain packaging, with informa-
tion for the consumer included. The current look of pre-
scription drugs would be the desired appearance. Research
data would need to be gathered from this experiment, and
increases in the number and types of controls would have
to be implemented if there was any evidence of increased
health or social harms.
As the new post prohibition model would need to be
based on evidence, new questions will need to be asked;
for example "To what extent can a dependent user of crack
cocaine be persuaded to substitute a less harmful weak
oral solution?". There are clues that this is possible in
some users as it has been observed that chewing coca
leaves can improve the lives of coca paste smokers [88].
This positive transition was also observed when depend-
ant coca paste smokers used coca tea and had fewer
relapses, reduced cravings and longer periods of absti-
nence with no medically adverse effects [89].
The author of this paper concludes that health and social
problems associated with currently illegal drugs cannot be
significantly controlled unless drug prohibition is funda-
mentally challenged. While harm reduction programs like
needle exchanges and supervised injection sites can
reduce health and social problems, they are insufficient as
they do not target the illegal market that supplies these
substances and creates many of the problems that are
associated with illegal drugs. If the above seven principles
were combined to produce a system of tightly regulated
access to concentrated stimulants and easier access to
weak oral solutions, incidence of diseases like HIV/AIDS
and hepatitis C, could be significantly reduced. As this sys-
tem would significantly reduce the illegal market and
associated criminality this model can also be predicted to
reduce many social harms.
Currently the blunt instrument of prohibition prevents us
from approaching drug use in our society with the level of
finesse that is required to fine tune a new public health
system that is responsive to evidence and evolves as new
data emerges. The public has had many years of exposure
to "drug war" messages that often directly and knowingly
contradict the research evidence [90,91], and usually
evoke a fear reaction. Changes in public perception will
require more policy research, and the creation of preven-
tion and education programs that are both factual and
honest. These programs will need to explore both the real-
ities of substance use and also examine the evidence that
details the ineffectiveness and harms created by drug pro-
hibition. Hopefully we live in a society that has enough
collective wisdom to mature beyond our current fear-
based approaches to allow the evolution of a public
health model that is guided instead by evidence and com-
passion.
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